| Literature DB >> 31831919 |
Akshaya Srikanth Bhagavathula1, Deepak Kumar Bandari2, Moien Khan3, Abdulla Shehab1.
Abstract
BACKGROUND: Suicide is a public health problem, and the number of paraphenylenediamine (PPD)-containing hair dye poisoning with suicidal intentions is increasing in developing countries. In order to better understand this situation, we aimed to conduct a systematic review and meta-analysis to estimate the prevalence and complications associated with hair dye poisoning in developing countries.Entities:
Keywords: Developing countries; hair dye poisoning; hair dye toxicity; household poisoning; paraphenylenediamine poisoning; suicides
Mesh:
Substances:
Year: 2019 PMID: 31831919 PMCID: PMC6892014 DOI: 10.4103/ijp.IJP_246_17
Source DB: PubMed Journal: Indian J Pharmacol ISSN: 0253-7613 Impact factor: 1.200
Figure 1Flow of information
Description of paraphenylenediamine-containing hair dye poisoning studies which are included in this systematic review and meta-analysis
| The study, author, year | Journal | Study location | Type of study | Period of study | Sample size | Study settings | Male: female | Mean or median age (years) | Conclusion |
|---|---|---|---|---|---|---|---|---|---|
| Venkatasubbaiah | Kadapa, India | Prospective | 2014-2015 | 386 | Causality | 97:289 | - | Awareness in the rural areas regarding the complications caused by PPD poisoning | |
| Tiwari | Gwalior, India | Prospective | 2008-2009 | 50 | Medical wards | 20:30 | - | Tracheostomy, endotracheal intubation with or without ventilation, and dialysis can decrease the mortality | |
| Mohammed | Khartoum, Sudan | Prospective | 2013-2014 | 40 | ENT department | 2:38 | 27.2 | Identified cardiac rhabdomyolysis in PPD poisoning | |
| Amarnath | Tirupati, India | Prospective(2,931 of 4,342 patients) | 2009-2011 | 27 | Causality and ENT department | 18:9 | 50.5 | Emergency tracheostomy is a reliable method of restoring the airway in hair dye poisoning | |
| Mahsud, 2015[ | Dera Ismail Khan, Pakistan | Prospective | 2013-2015 | 38 | Emergency ward | 2:36 | 22.08±6.4 | PPD poisoning causing asphyxia and respiratory failure leading to death | |
| Naqvi | Karachi, Pakistan | Prospective | 2010-2014 | 75 | Nephrology ward | - | 28.2±11.2 | PPD poisoning is a contributing factor for toxic rhabdomyolysis | |
| Balasubramanian | Thoothukudi, India | Prospective | April-December 2010 | 125 | Intensive care unit | 39:86 | 24 | Time of hospital presentation is an important risk factor for oropharyngeal edema in hair dye poisoning | |
| Shigidi | Khartoum, Sudan | Prospective | 2012-2013 | 30 | Emergency | 2:28 | 25.6±4.2 | Hair dye poisoning patients with Acute 9kidney injury re10quired dialysis | |
| Sugunakar | Amalapuram, India | Retrospective | 2005-2006 | 18 | Hospital admission | 4:14 | - | PPD intoxication needed aggressive treatment support | |
| Gella | Kadapa, India | Prospective | March-September 2011 | 419 | Intensive care unit and medical wards | 126:293 | - | Cardiorespiratory failure, myocarditis, and acute renal failure leading to death | |
| Rebgui | Rabat, Morocco | Retrospective | 1996-2007 | 102 | Poison control and drug monitoring center | 18:84 | 17.3±15.6 | PPD import and sales should be banned in Morocco | |
| Gupta and Singh, 2013[ | Gwalior, India | Prospective | - | 36 | Hospital admissions | - | - | Emergency tracheostomy tends to decrease the mortality in PPD poisoning | |
| Elgamel and Ahmed, 2013[ | Khartoum, Sudan | Retrospective | June-December 2008 | 200 | ENT department | 39:161 | - | Emergency tracheostomy tends to decrease the mortality in PPD poisoning | |
| Khuhro | Nawabshah, Pakistan | Prospective | 2009-2012 | 16 | Intensive care unit | 2:14 | 25.8±5.6 | PPD poisoning associated with high mortality | |
| Nirmala and Ganesh, 2012[ | Thoothukudi, India | Retrospective | 2009-2010 | 108 | ENT department | 38:70 | 24.7±6.5 | Needed public awareness of hair dye | |
| Osman | Gezira, Sudan | Retrospective | 2006-2007 | 55 | Renal diseases and surgery | 2:53 | - | Hair dye poisoning containing PPD is the main causative factor of ARF | |
| Kindle | Nellore, India | Retrospective | 2008-2011 | 50 | Emergency ward | 9:41 | 23±7.8 | Supervasmol-33 is an emerging alternative to organophosphorus poisoning. | |
| Radhika | Kadapa, India | Prospective | January-April 2010 | 264 | Causality ward | 93:171 | - | Banning hair dyes in some parts of India | |
| Jain | Jhansi, India | Prospective | 2000-2011 | 1595 | Medicine department | 381:1214 | - | Myocarditis is a fatal complication due to ingestion of PPD-20-containing hair dye with >10 grams of dose | |
| Sandeep Reddy | Tirupati, India | Prospective | 2007-2011 | 81 | Hospital admissions | 43:38 | - | Acute kidney injury testifies the severity of intoxication and poor prognosis | |
| Prasad | Tirupati, India | Retrospective | 2008-2010 | 81 | Emergency | - | - | Biochemical changes are the cornerstone for early diagnosis of hair dye poisoning complications | |
| Jain | Jhansi, India | Prospective | 2004-2009 | 1020 | Medicine department | 286:734 | - | Early therapeutic intervention is essential for PPD hair dye poisoning | |
| Charra | Casablanca, Morocco | Prospective | 2010 | 21 | Intensive care unit | 4:17 | 20 | Inflammatory stress, pro-inflammatory power, and immunomodulative actions were causing cytotoxicity in hair dye poisoning patients | |
| Chrispal | Vellore, India | Retrospective | 2006-2009 | 13 | Hospital admissions | 2:11 | 27.2±8.7 | Early referral and aggressive management could reduce the mortality | |
| Shalaby | Cairo, Egypt | Retrospective | 2001-2008 | 25 | Poison control center | 7:18 | 35±10.5 | Early recognition of complications and prompt treatment are necessary for successful outcome | |
| Murugan and Bairagi, 2010[ | Karaikal, India | Retrospective | 2008-2009 | 9 | Hospital deaths | 0:9 | Female gender aged between 20 and 30 years was risk for suicidal exposure | ||
| Sahay | Hyderabad, India | Prospective | - | 30 | Nephrology | 24:6 | 26.9±4.9 | Hair dye poisoning is an important cause of acute renal failure and required respiratory and hemodynamic support for recovery | |
| Kaballo | Khartoum, Sudan | Retrospective | 2003-2004 | 89 | Nephrology | 57:32 | 39±19.4 | Acute tubular necrosis was associated with PPD poisoning | |
| Filali | Rabat, Morocco | Retrospective | 1992-2002 | 374 | Poison control center | 86:288 | - | PPD poisoning has serious consequences which may eventually lead to death. | |
| Kallel | Sfax, Tunisia | Retrospective | 1994-2000 | 19 | Intensive care unit | - | 27.9±16.8 | PPD intoxication was associated with respiratory, muscular, renal moreover, hemodynamic syndromes | |
| Fatihi el | Casablanca, Morocco | Prospective | 1984-1994 | 13 | Nephrology | - | - | PPD can cause rhabdomyolysis | |
| Suliman | Khartoum, Sudan | Retrospective | 1983-1993 | 150 | Hospital admissions | 30:120 | 40 | PPD poisoning causes severe side effect on oral ingestion |
The systematic review includes 32 studies, n=5559; meta-analysis - 29 studies, n=5448; *Studies excluded from the meta-analysis. PPD=Paraphenylenediamine, ENT=Ear, nose, and throat, ARF=Acute renal failure
Figure 2Ingestion of paraphenylenediamine-containing hair dye with suicidal intentions
Figure 3Cervicofacial edema–angioneurotic edema in hair dye ingested patients
Figure 4Analysis of tracheotomy intervention in paraphenylenediamine-containing hair dye poisoning
Figure 5Occurrence of acute renal failure in hair dye poisoning patients
Figure 6Analysis of hair dye intoxication mortality
Figure 7Gender differences in hair dye poisoning patients
PRISMA 2009 checklist
| Section/topic | # | Checklist item | Reported on page# |
|---|---|---|---|
| Title | |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both | 1 |
| Abstract | |||
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number | 2 |
| Introduction | |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 4 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS) | 5 |
| Methods | |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., web address), and, if available, provide registration information including registration number | 5 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale | 6 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched | 6 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated | 6 |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis) | 6 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators | 6 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made | 7 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 7 |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means) | 7 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., | 7 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 7 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | 7 |
| Results | |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. | 8 |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations | 8 |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12) | 8 |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) Simple summary data for each intervention group (b) Effect estimates and confidence intervals, ideally with a forest plot | 9 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency | 9 |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15) | 10 |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see item 16]) | 10 |
| Discussion | |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers) | 11 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias) | 14 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research | 14 |
| Funding | |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review | 14 |
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6):e1000097. doi: 10.1371/journal.pmed1000097. For more information, visit: www.prisma-statement.org